BridgeBio Pharma, Inc. Retained Earnings
BridgeBio Pharma, Inc. (BBIO) had Retained Earnings of -$4.14 billion as of 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Balance Sheet › Equity › Equity, Including Portion Attributable to Noncontrolling Interest › Equity, Attributable to Parent
us-gaap:RetainedEarningsAccumulatedDeficit · last filed 2026-08-10
- 2026-06-30: Retained Earnings (Accumulated Deficit) -$4.14B.
- 2026-03-31: Retained Earnings (Accumulated Deficit) -$3.99B.
- 2025-12-31: Retained Earnings (Accumulated Deficit) -$3.82B.
- 2025-09-30: Retained Earnings (Accumulated Deficit) -$3.63B.
| Period end | Retained Earnings (Accumulated Deficit) | Retained Earnings (Accumulated Deficit) as first filed |
|---|---|---|
| 2026-06-30 | -$4.14B 10-Q · filed 2026-08-10 | |
| 2026-03-31 | -$3.99B 10-Q · filed 2026-05-07 | |
| 2025-12-31 | -$3.82B 10-Q · filed 2026-08-10 | |
| 2025-09-30 | -$3.63B 10-Q · filed 2025-10-29 | |
| 2025-06-30 | -$3.45B 10-Q · filed 2025-08-05 | |
| 2025-03-31 | -$3.26B 10-Q · filed 2025-04-29 | |
| 2024-12-31 | -$3.10B 10-K · filed 2026-02-24 | |
| 2024-09-30 | -$2.83B 10-Q · filed 2024-11-12 | |
| 2024-06-30 | -$2.67B 10-Q · filed 2024-08-01 | |
| 2024-03-31 | -$2.60B 10-Q · filed 2024-05-02 | |
| 2023-12-31 | -$2.56B 10-K · filed 2025-02-20 | |
| 2023-09-30 | -$2.39B 10-Q · filed 2023-11-02 | |
| 2023-06-30 | -$2.22B 10-Q · filed 2023-08-03 | |
| 2023-03-31 | -$2.06B 10-Q · filed 2023-05-04 | |
| 2022-12-31 | -$1.92B 10-K · filed 2024-02-22 | |
| 2022-09-30 | -$1.78B 10-Q · filed 2022-11-03 | |
| 2022-06-30 | -$1.64B 10-Q · filed 2022-08-04 | |
| 2022-03-31 | -$1.63B 10-Q · filed 2022-05-05 | |
| 2021-12-31 | -$1.44B 10-K · filed 2023-02-23 | |
| 2021-09-30 | -$1.29B 10-Q · filed 2021-11-04 | |
| 2021-06-30 | -$1.13B 10-Q · filed 2021-08-05 | |
| 2021-03-31 | -$1.04B 10-Q · filed 2021-05-06 | |
| 2021-01-01 | -$874.43M 10-K · filed 2022-02-25 | |
| 2020-12-31 | -$888.75M 10-K · filed 2022-02-25 | |
| 2020-09-30 | -$768.77M 10-Q · filed 2020-11-05 | |
| 2020-06-30 | -$652.91M 10-Q · filed 2020-08-11 | |
| 2020-03-31 | -$531.88M 10-Q · filed 2020-05-14 | |
| 2019-12-31 | -$440.03M 10-K · filed 2021-02-25 | |
| 2019-09-30 | -$366.57M 10-Q · filed 2019-11-08 | |
| 2019-06-30 | -$306.59M 10-Q · filed 2020-08-11 | -$69.00K 10-Q · filed 2019-08-14 |
| 2019-03-31 | -$240.63M 10-Q · filed 2020-05-14 | |
| 2018-12-31 | -$179.44M 10-K · filed 2020-03-03 | |
| 2017-12-31 | -$48.70M 10-K · filed 2020-03-03 | |
| 2016-12-31 | -$18.13M 10-K · filed 2020-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |